Our study showed that the expression of CD38 and PARP genes, well-known NAD-consuming enzymes, was associated with the type I IFN signature in SLE patients (Fig. 6a) and was inducible by IFNα exposure in vitro (Fig. 6b). This evidence concerns the gene CD38 and systemic lupus erythematosus.